Synairgen reports 'significant progress'

Share

• Copy link
• Facebook
• X
• Linkedin
• Whatsapp
• Pinterest

Share this article

Join the conversation

Follow us

Add us as a preferred source on Google

Newsletter

Get the MoneyWeek Newsletter

Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Contact me with news and offers from other Future brands Receive email from us on behalf of our trusted partners or sponsors

---

By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.

You are now subscribed

Your newsletter sign-up was successful

---

Want to add more newsletters?

Twice daily

MoneyWeek

Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Signup +

Four times a week

Look After My Bills

Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!

Signup +

---

An account already exists for this email address, please log in.

Subscribe to our newsletter

Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June.

The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the potential of SNG001 as a broad spectrum antiviral.

In October Synairgen submitted a competitive contract tender to the US National Institute of Allergy and Infectious Diseases, which, if successful, would result in a contract being awarded in the second half of 2013.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Meanwhile, analysis of gene and protein biomarkers in samples from the Phase II study in asthma have been initiated, and advancements have been made in its clinical development plan for both the asthma and Chronic Obstructive Pulmonary Disease (COPD).

The company has also expanded its patent portfolio through the grant of a US patent for compounds that induce interferon beta to treat or prevent rhinovirus infections.

Richard Marsden, Chief Executive, said: "This has been an extremely busy period for the company. We have significantly progressed discussions with various potential licensing partners for SNG001 in asthma and COPD and commenced biomarker and further analysis of the samples from the Phase II asthma study.

"In addition, the patent portfolio has been substantially enhanced. We are excited by the potential of our lead programmes and looking forward to progressing their development in 2013."

The share price rose 3.23% to 48p by 11:35.

NR